MVX-01 is under clinical development by Matrivax Research & Development and currently in Phase I for Streptococcal Pneumonia. According to GlobalData, Phase I drugs for Streptococcal Pneumonia have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MVX-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MVX-01 overview
MVX-01 is under development for the prevention and treatment of Streptococcal pneumonia infections. The vaccine candidate comprises of a pneumolysin-choline binding protein A (CbpA) fusion protein. It is being developed based on Protein Capsular Matrix Vaccine (PCMV) technology.
See Also:
Matrivax Research & Development overview
Matrivax Research & Development (Matrivax) is a biotechnology company developing human vaccines for the prevention and treatment of life-threatening infectious diseases. It is a privately-held company funded by Morningside Investments and based in the biotech hub of Boston, MA. The company headquartered in Boston, Massachusetts, the US.
For a complete picture of MVX-01’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
